more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.18 USD

+0.86 (1.58%)

Updated Nov 4, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Walmart Earnings & the State of the Consumer

by Sheraz Mian Published on May 16,2024

We discuss what Walmart's blockbuster results tell us about the health of the consumer economy.

earnings

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

by Ekta Bagri Published on May 16,2024

Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.

Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

by Zacks Equity Research Published on May 16,2024

Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research Published on May 15,2024

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

BMYPositive Net Change

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

by Zacks Equity Research Published on May 13,2024

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

by Zacks Equity Research Published on May 09,2024

Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.

A Look at Pharma ETFs Post Q1 Earnings

by Sweta Killa Published on May 07,2024

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

by Zacks Equity Research Published on May 03,2024

Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.

biotechnology

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

by Zacks Equity Research Published on May 02,2024

Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research Published on April 30,2024

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

BMYPositive Net Change

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

by Zacks Equity Research Published on April 26,2024

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

by Zacks Equity Research Published on April 25,2024

Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

by Zacks Equity Research Published on April 25,2024

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BMYPositive Net Change

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research Published on April 25,2024

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research Published on April 25,2024

BMYPositive Net Change

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

by Sweta Killa Published on April 24,2024

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

etfs
medical

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

by Ahan Chakraborty Published on April 24,2024

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research Published on April 23,2024

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

by Zacks Equity Research Published on April 22,2024

Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.

Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research Published on April 22,2024

Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

BMYPositive Net Change

Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline

by Zacks Equity Research Published on April 18,2024

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

by Zacks Equity Research Published on April 17,2024

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

biotechs